ReviewDrugs2005
Escitalopram: a review of its use in the management of major depressive disorder.
Review in Drugs, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.PharmacoEconomics · 2013Pooled it
- R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.British journal of clinical pharmacology · 2016Trial
- Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study.Journal of affective disorders · 2013Trial
- Trial
- Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.PharmacoEconomics · 2008Trial
- Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study.Psychopharmacology · 2007Trial
- A comparative analysis of vortioxetine vs. escitalopram on the clinical profile of patients with major depressive disorder.Journal of family medicine and primary care · 2026Article
- Relationship between hippocampal volume and treatment response before and after escitalopram administration in patients with depression.Translational psychiatry · 2025Article
- Citalopram & escitalopram: Mechanisms of cardiotoxicity, toxicology predisposition and risks of use in geriatric & hemodialysis populations.Global cardiology science & practice · 2024Review
- Modulation of serotonin transporter expression by escitalopram under inflammation.Communications biology · 2024Article
- Effect of cognitive retraining treatment in mild to moderate depressive disorders.Psicologia, reflexao e critica : revista semestral do Departamento de Psicologia da UFRGS · 2023Article
- Article
- Escitalopram co-prescription in anastrozole-treated breast cancer patients.Northern clinics of Istanbul · 2022Article
- Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis.BMJ medicine · 2022Article
- Characterization of gut microbiome in mice model of depression with divergent response to escitalopram treatment.Translational psychiatry · 2021Article
- Minocycline alters behavior, microglia and the gut microbiome in a trait-anxiety-dependent manner.Translational psychiatry · 2019Article
- Review
- Socioeconomic determinants affecting the access and utilization of depression care services in immigrants: A population-based study.PloS one · 2019Article
- Pharmacokinetics of antidepressants in patients with hepatic impairment.Clinical pharmacokinetics · 2014Review
- Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability.Patient preference and adherence · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Escitalopram (Cipralex, Lexapro), the active S-enantiomer of the racemic selective serotonin reuptake inhibitor (SSRI) citalopram (RS-citalopram), is a highly selective inhibitor of the serotonin transporter protein. It possesses a rapid onset of antidepressant activity, and is an effective and generally well tolerated treatment for moderate-to-severe major depressive disorder (MDD). Pooled analyses from an extensive clinical trial database suggest that escitalopram is consistently more effective than citalopram in moderate-to-severe MDD. Preliminary studies suggest that escitalopram is as effective as other SSRIs and the extended-release (XR) formulation of the serotonin/noradrenaline (norepinephrine) reuptake inhibitor venlafaxine, and may have cost-effectiveness and cost-utility advantages. However, additional longer-term, comparative studies evaluating specific efficacy, tolerability, health-related quality of life and economic indices would be helpful in definitively positioning escitalopram relative to these other agents in the treatment of MDD. Nevertheless, available clinical and pharmacoeconomic data indicate that escitalopram is an effective first-line option in the management of patients with MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.